JACKSON CENTER, Pa., Feb. 20, 2018 (GLOBE NEWSWIRE) — Premier Biomedical, Inc. (OTC:BIEI) announced today they have signed a distribution agreement with Okeechobee Discount Drugs to sell and distribute Premier’s pain relief products. This agreement will make Premier’s products available locally in the Okeechobee, Florida area, and complements existing internet sales at Premier’s website, www.painreliefmeds.com, and other physical locations announced in earlier press releases.
Steven Nelson, Chief Pharmacist and Owner of Okeechobee Discount Drugs commented, “At Okeechobee Discount Drugs, we are always looking for the best health outcomes for our patients. We are excited to be partnering with Premier Biomedical to bring CBD/hemp products, such as roll on oils, patches and topical sprays, to our shelves as a natural alternative for pain relief. As a recent recipient of a knee replacement, I used the topical spray and roll-on oil around the areas of greatest discomfort on my leg. Not only did I receive pain relief, but it left me feeling more mobile and with less of an overall ache in the leg.”
William A. Hartman, President & CEO of Premier Biomedical, stated, “We are very excited that we have been able to reach agreement with Okeechobee Discount Drugs to carry and promote our products through their facility. Our strategy continues to be to have a two-fold distribution network – direct retailers, and our on-line sales. Once people try our products, they will agree that they outperform every other competitive product in relieving pain and suffering.”
For more information please contact:
About Okee Drugs
Okeechobee Discount Drugs is family owned and operated. Established in 1982 with the goal of providing the community with a pharmacy that had a hometown feel serving the downtown Okeechobee area.
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTC:BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents, and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the University of Texas at El Paso (UTEP). In 2016, the company began developing a line of all-natural pain relief products which they began selling in early 2017 to address the rising opioid addiction problem. The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTC marketplace maintained by OTC Markets Group, Inc. under the ticker symbol “BIEI.” For more information please visit our website: http://www.premierbiomedical.com/.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
Source: Uptick Newswire